Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
S-adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial
Autore:
Mato, JM; Camara, J; de Paz, JF; Caballeria, L; Coll, S; Caballero, A; Garcia-Buey, L; Beltran, J; Benita, V; Caballeria, J; Sola, R; Moreno-Otero, R; Barrao, F; Martin-Duce, A; Correa, JA; Pares, A; Barrao, E; Garcia-Magaz, I; Puerta, JL; Moreno, J; Boissard, G; Ortiz, P; Rodes, J;
Indirizzi:
Univ Navarra, Dept Med, Div Hepatol & Gene Therapy, E-31080 Pamplona, Spain Univ Navarra Pamplona Spain E-31080 ene Therapy, E-31080 Pamplona, Spain Europharma SA, Grp Boehringer Ingelheim Espana SA, Madrid, Spain Europharma SA Madrid Spain oehringer Ingelheim Espana SA, Madrid, Spain Hosp Principe Asturias, Unidad Digest, Madrid, Spain Hosp Principe Asturias Madrid Spain urias, Unidad Digest, Madrid, Spain Univ Barcelona, Alcohol & Liver Units, Hosp Clin & Prov, Barcelona, Spain Univ Barcelona Barcelona Spain nits, Hosp Clin & Prov, Barcelona, Spain UnivSpainnoma Barcelona, Hosp Mar, Serv Aparato Digest, E-08003 Barcelona,Univ Autonoma Barcelona Barcelona Spain E-08003 gest, E-08003 Barcelona, Hosp Clin Univ Granada, Granada, Spain Hosp Clin Univ Granada Granada Spain Clin Univ Granada, Granada, Spain Hosp Princesa, Unidad Hepatol, Madrid, Spain Hosp Princesa Madrid SpainHosp Princesa, Unidad Hepatol, Madrid, Spain Hosp Clin Univ Zaragoza, Serv Digest, Zaragoza, Spain Hosp Clin Univ Zaragoza Zaragoza Spain za, Serv Digest, Zaragoza, Spain Knoll Pharmaceut Spa, Biometr Unit, Milan, Italy Knoll Pharmaceut Spa Milan Italy maceut Spa, Biometr Unit, Milan, Italy
Titolo Testata:
JOURNAL OF HEPATOLOGY
fascicolo: 6, volume: 30, anno: 1999,
pagine: 1081 - 1089
SICI:
0168-8278(199906)30:6<1081:SIALCA>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
ADENOSYL-L-METHIONINE; PERFUSED-RAT-LIVER; INTRAHEPATIC CHOLESTASIS; N-ACETYLCYSTEINE; PROTECTIVE ROLE; SYNTHETASE; INJURY; DISEASE; METABOLISM; ETHANOL;
Keywords:
AdoMet; alcohol; cirrhosis; S-adenosyl-methionine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
42
Recensione:
Indirizzi per estratti:
Indirizzo: Mato, JM UnivSpainrra, Dept Med, Div Hepatol & Gene Therapy, S-N, E-31080 Pamplona, Univ Navarra S-N Pamplona Spain E-31080 , S-N, E-31080 Pamplona,
Citazione:
J.M. Mato et al., "S-adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial", J HEPATOL, 30(6), 1999, pp. 1081-1089

Abstract

Background/Aim: The efficacy of S-adenosylmethionine (AdoMet) in the treatment of liver cc:ll injury has been demonstrated in several experimental models. The aim of this study was to investigate the effects of AdoMet treatment in human alcoholic liver cirrhosis,Methods: A randomized, double-blind trial was performed in 123 patients treated with AdoMet (1200 mg/day, orally) or placebo for 2 years, All patients had alcoholic cirrhosis, and histologic confirmation of the diagnosis wasavailable in 84% of the cases. Seventy-five patients were in Child class A, 40 in class B, and 8 in class C, Sixty-two patients received AdoMet and 61 received placebo,Results: At inclusion into the trial no significant differences were observed between the two groups with respect to sex, age, previous episodes of major complications of cirrhosis, Child classification and liver function tests. The overall mortality/liver transplantation at the end of the trial decreased from 30% in the placebo group to 16% in the AdoMet group, although the difference was not statistically significant (p=0.077), When patients in Child C class were excluded from the analysis, the overall mortality/liver transplantation was significantly greater in the placebo group than in the AdoMet group (29% vs 12%, p=0.025), and differences between the two groups in the 2-year survival curves (defined as the time to death or liver transplantation) were also statistically significant (p=0.046),Conclusions: The present results indicate that longterm treatment with AdoMet may improve survival or delay liver transplantation in patients with alcoholic liver cirrhosis, especially in those with less advanced liver disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 15:56:35